Apyx Medical submits 510k premarket notification to FDA for AYON BCS

Apyx Medical (APYX) announces it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for the AYON Body Contouring System, BCS. “We believe the AYON Body Contouring System is a game changer for surgeons, one that will differentiate and further position Apyx Medical as the premier aesthetic surgical company,” said Charlie Goodwin, President, and CEO of Apyx Medical Corporation. “We are pleased to make this announcement almost 90 days earlier than originally expected, a testament to the capabilities of the hard-working research, development, quality and regulatory teams at Apyx Medical.”